Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Shares Outstanding (Weighted Average) (2021 - 2025)

Historic Shares Outstanding (Weighted Average) for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $74.7 million.

  • Kiniksa Pharmaceuticals International's Shares Outstanding (Weighted Average) rose 416.6% to $74.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.7 million, marking a year-over-year increase of 416.6%. This contributed to the annual value of $71.4 million for FY2024, which is 194.87% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Shares Outstanding (Weighted Average) of $74.7 million as of Q3 2025, which was up 416.6% from $73.4 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Shares Outstanding (Weighted Average) peaked at $74.7 million during Q3 2025, and registered a low of $68.3 million during Q1 2021.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Shares Outstanding (Weighted Average) had a median value of $69.9 million in 2023 and averaged $70.4 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Shares Outstanding (Weighted Average) soared by 88.92% in 2023, and later skyrocketed by 416.6% in 2025.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's Shares Outstanding (Weighted Average) stood at $68.6 million in 2021, then rose by 1.17% to $69.4 million in 2022, then rose by 0.98% to $70.1 million in 2023, then grew by 1.95% to $71.4 million in 2024, then increased by 4.61% to $74.7 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $74.7 million in Q3 2025, compared to $73.4 million in Q2 2025 and $72.6 million in Q1 2025.